estradiol; norethindrone acetate; relugolix - Profile
✉ Email this page to a colleague
What are the generic drug sources for estradiol; norethindrone acetate; relugolix and what is the scope of patent protection?
Estradiol; norethindrone acetate; relugolix
is the generic ingredient in one branded drug marketed by Sumitomo Pharma Am and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Estradiol; norethindrone acetate; relugolix has one hundred and seventy-three patent family members in forty countries.
Summary for estradiol; norethindrone acetate; relugolix
| International Patents: | 173 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for estradiol; norethindrone acetate; relugolix |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for estradiol; norethindrone acetate; relugolix
Generic Entry Date for estradiol; norethindrone acetate; relugolix*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MYFEMBREE | Tablets | estradiol; norethindrone acetate; relugolix | 1 mg/0.5 mg/40 mg | 214846 | 1 | 2024-12-18 |
US Patents and Regulatory Information for estradiol; norethindrone acetate; relugolix
Expired US Patents for estradiol; norethindrone acetate; relugolix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | ⤷ Start Trial | ⤷ Start Trial |
| Sumitomo Pharma Am | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for estradiol; norethindrone acetate; relugolix
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Uruguay | 35058 | ⤷ Start Trial | |
| China | 104703992 | ⤷ Start Trial | |
| China | 110312512 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2018060501 | ⤷ Start Trial | |
| Cyprus | 1121641 | ⤷ Start Trial | |
| Russian Federation | 2331648 | СОЕДИНЕНИЯ ТИЕНОПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ (THIENOPYRIMIDINE COMPOUNDS AND THEIR APPLICATION) | ⤷ Start Trial |
| Australia | 2022241582 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for estradiol; norethindrone acetate; relugolix
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1591446 | 51/2021 | Austria | ⤷ Start Trial | PRODUCT NAME: RELUGOLIX ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1565 (MITTEILUNG) 20210720 |
| 1380301 | 2009C/007 | Belgium | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 1591446 | LUC00240 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: RELUGOLIX OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1565 20210720 |
| 1453521 | 300814 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1214076 | C01214076/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 0398460 | C300221 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
| 1591446 | CR 2021 00048 | Denmark | ⤷ Start Trial | PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REG. NO/DATE: EU/1/21/1565 20210720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
